Market Overview

BTIG Equity Research Bullish On Lombard Medical Inc


Analysts at BTIG Equity Research initiated coverage on Lombard Medical Inc (NASDAQ: EVAR) with a Buy rating and $9 price target Thursday.

Sean Lavin highlighted drivers for the firm:

The company's innovative Aorfix Stent graft has two significant opportunities. It is the only FDA label for highly-angulated aneurysm necks and analysts feel the stent may have advantages in tortuous iliacs.

The company is also in a compelling and expanding market. Analysts estimate the Endovascular aneurysm repair market is $1.5 billion and growing roughly six percent annually.

Moreover, Lavin feels that Lombard Medical is an attractive acquisition candidate given its enterprise value and potential market.

Shares of Lombard Medical recently traded at $7.77, up 7.9 percent.

Latest Ratings for EVAR

Aug 2016MaintainsEqual-Weight
Nov 2015DowngradesOverweightEqual-Weight
Nov 2015DowngradesBuyNeutral

View More Analyst Ratings for EVAR
View the Latest Analyst Ratings

Posted-In: BTIG Research Sean LavinPrice Target Initiation Analyst Ratings


Related Articles (EVAR)

View Comments and Join the Discussion!

Green Dot Corporation To Offer Tax Refund Service Through Acquisition

Google Inc Technicals Still Showing Relative Weakness And A Bearish Setup